Related Experiment Video
Updated: Sep 30, 2025
Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
Effect of Different MPTP Administration Intervals on Mouse Models of Parkinson's Disease
Yuanyuan Ma1,2,3, Qiongwen Rong1,2,3
1Department of Neurology, The First Affiliated Hospital of Hainan Medical University, Haikou 570102, China.
Objective:
To research the effect of different 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) administration intervals on the behavior and pathology of mouse models of Parkinson's disease.
Methods:
Eighteen C57 male mice were divided into a control group, subacute model group, and chronic model group (6 mice per group). Animal models of Parkinson's disease were built according to MPTP administration. The behavior of mice was determined through an open-field test and pole test. Tyrosine hydroxylase expression in brain tissues was checked by immunohistochemistry and western blot.
Result:
In the open-field test, the total activity distance in the chronic model group (1271.05 ± 207.93 cm) was reduced significantly compared with that of the control group (1964.21 ± 379.77 cm), while the distance had no significant differences in the subacute model group (1950.57 ± 273.54 cm). At the same time, the number of times the mice crossed the center grid in the chronic model group (3.17 ± 1.17) was reduced compared with that in the control group (11.67 ± 6.65), while there were few differences in the subacute model group (9.33 ± 2.81). In the pole test, the climbing time (8.49 ± 1.44 s) and total rest time (103.64 ± 26.57 s) of mice in the chronic model group were longer than those in the control group, respectively (4.31 ± 0.70 s, 45.21 ± 14.36 s), while there were no significant differences in the subacute model group (4.51 ± 0.48 s, 52.44 ± 25.98 s). Besides, compared with the control group, TH expression in the subacute model group and chronic model group was reduced notably, and the changes of TH expression in the chronic model group were more significant.
Conclusion:
There is a little loss of midbrain dopaminergic neurons in the subacute Parkinson's disease mouse models induced by continuous MPTP administration, but there is no effect on the behavior. Long interval MPTP-induced chronic Parkinson's disease mouse models lose a lot of dopaminergic neurons, which is accompanied by anxiety-like behaviors in addition to motor dysfunction.
Insights
Chronic MPTP administration in mice significantly impairs motor function and reduces tyrosine hydroxylase expression, mimicking Parkinson's disease pathology. Subacute models show minimal behavioral changes despite some neuronal loss.
Area of Science:
- Neuroscience
- Pharmacology
- Animal Models
Background:
- Parkinson's disease (PD) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons.
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) is a neurotoxin commonly used to create PD mouse models.
- The impact of MPTP administration intervals on PD model development requires further investigation.
Purpose of the Study:
- To investigate the differential effects of subacute versus chronic MPTP administration on Parkinson's disease mouse models.
- To assess behavioral and pathological changes in response to varying MPTP dosing regimens.
Main Methods:
- Establishment of Parkinson's disease mouse models using MPTP with distinct administration intervals (subacute and chronic).
- Behavioral assessment through open-field and pole tests.
- Quantification of tyrosine hydroxylase (TH) expression in brain tissue via immunohistochemistry and Western blot.
Main Results:
- Chronic MPTP administration significantly reduced locomotor activity and center grid crossings in the open-field test compared to controls.
- The pole test revealed increased climbing and rest times in the chronic model group, indicating motor dysfunction.
- Both subacute and chronic MPTP models exhibited reduced TH expression, with more pronounced effects in the chronic group.
- Subacute MPTP models showed no significant behavioral deficits despite some TH reduction.
Conclusions:
- Subacute MPTP administration results in minimal behavioral impairment and limited dopaminergic neuron loss.
- Chronic MPTP administration induces significant motor deficits and substantial dopaminergic neurodegeneration, accompanied by anxiety-like behaviors.
- Administration intervals critically influence the development and manifestation of MPTP-induced Parkinson's disease phenotypes in mice.
